Mörth, Charlott http://orcid.org/0000-0002-2308-6666
Sabaa, Amal Abu
Freyhult, Eva
Christersson, Christina
Hashemi, Jamileh
Hashemi, Nashmil
Kamali-Moghaddam, Masood
Molin, Daniel
Höglund, Martin
Eriksson, Anna
Enblad, Gunilla
Funding for this research was provided by:
Cancerfonden
Article History
Received: 10 October 2020
Accepted: 20 January 2021
First Online: 3 February 2021
Change Date: 7 April 2021
Change Type: Update
Change Details: Open Access funding note to be added to fulfill the contractual requirement of the Germany fully OA/Sweden fully OA agreement. The article has been updated.
Ethics approval and consent to participate
: The U-CAN project, including this study, has been approved by the Regional Ethics Committee (EC) of Uppsala-Örebro (Ups 2012/198, 210/198/1, 2014/233). Data collection in the EpiHealth study and usage of the material in this project has been approved by the EC of Uppsala (Dnr 2010/402: 2010-12-01, 2011-11-17, 2015/179). The EpiHealth study is approved by the Swedish Data Protection Authority. There was no need for written consent or consent for publication.
: There are no competing interests. Christina Christersson has received personal fees (speakers fees, advisory board) from Boehringer Ingelheim, Bristol Myers Squibb and Bayer outside the submitted work. Daniel Molin has received speaker fees from Merck, Bristol Myers Squibb, Takeda and Roche outside the submitted work.There are no other potential conflicts of interest.